TY - JOUR
T1 - Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine
AU - Dumitru, Alina F.
AU - Shamji, Mohamed
AU - Wagenmann, Martin
AU - Hindersin, Simone
AU - Scheckenbach, Kathrin
AU - Greve, Jens
AU - Klenzner, Thomas
AU - Hess, Lorenzo
AU - Nebel, Sabine
AU - Zimmermann, Christian
AU - Zahner, Catherine
AU - Schmidt-Weber, Carsten B.
AU - Chaker, Adam M.
N1 - Funding Information:
Supported by Max Zeller Söhne AG, Romanshorn , Switzerland.
Funding Information:
Disclosure of potential conflict of interest: T. Klenzner has received research support from Max Zeller Sohne AG, Romanshorn , Switzerland. L. Hess has provided legal consultation/expert witness testimony on the topics of Statistical Analysis and Statistical Report. A. M. Chaker has given lectures sponsored by GlaxoSmithKline and has received research support from Zeller AG , Switzerland, and Novartis Pharma AG , Switzerland. The rest of the authors have declared that they have no conflict of interest.
PY - 2011/6
Y1 - 2011/6
N2 - Background: Allergic rhinitis symptoms of itching, sneezing, rhinorrhea, and nasal obstruction significantly decrease patients' quality of life. Compared with histamine and leukotriene receptor antagonists, the petasol butenoate complex Ze 339 displays pharmacologically distinct properties. In vitro it inhibits the biosynthesis of leukotrienes and mediator release from activated eosinophils. Objective: This study aimed to assess the efficacy and mode of action of Ze 339, desloratadine, and placebo on allergic rhinitis symptoms, nasal airflow, and local mediator levels after unilateral nasal allergen provocation. Methods: In this double-blind, randomized, crossover study 18 subjects with allergic rhinitis to grass pollen received Ze 339, desloratadine, and placebo for 5 days before nasal allergen challenge with grass pollen extract. Rhinomanometry, symptom assessment, and local inflammatory mediator measurement were performed during the 24 hours after allergen challenge. Results: With Ze 339, the patient's time to recovery (5.4 ± 1.6 hours) from nasal obstruction after allergen challenge (time for return to 90% of baseline value ± SEM) was significantly shorter than with placebo (9.1 ± 2.3 hours, P = .035) and desloratadine (10.7 ± 2.5 hours, P = .022). Likewise, Ze 339's standardized symptom assessment for nasal obstruction (3.2 ± 1.3 hours) showed significantly faster relief (time for return to baseline value ± SEM compared with placebo, 8.3 ± 2.4 hours; P = .027) and desloratadine (4.5 ± 1.2 hours, P = .030). One interesting finding was that Ze 339 significantly reduced IL-8 and leukotriene B4 levels in nasal secretions before challenge. Conclusion: When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis.
AB - Background: Allergic rhinitis symptoms of itching, sneezing, rhinorrhea, and nasal obstruction significantly decrease patients' quality of life. Compared with histamine and leukotriene receptor antagonists, the petasol butenoate complex Ze 339 displays pharmacologically distinct properties. In vitro it inhibits the biosynthesis of leukotrienes and mediator release from activated eosinophils. Objective: This study aimed to assess the efficacy and mode of action of Ze 339, desloratadine, and placebo on allergic rhinitis symptoms, nasal airflow, and local mediator levels after unilateral nasal allergen provocation. Methods: In this double-blind, randomized, crossover study 18 subjects with allergic rhinitis to grass pollen received Ze 339, desloratadine, and placebo for 5 days before nasal allergen challenge with grass pollen extract. Rhinomanometry, symptom assessment, and local inflammatory mediator measurement were performed during the 24 hours after allergen challenge. Results: With Ze 339, the patient's time to recovery (5.4 ± 1.6 hours) from nasal obstruction after allergen challenge (time for return to 90% of baseline value ± SEM) was significantly shorter than with placebo (9.1 ± 2.3 hours, P = .035) and desloratadine (10.7 ± 2.5 hours, P = .022). Likewise, Ze 339's standardized symptom assessment for nasal obstruction (3.2 ± 1.3 hours) showed significantly faster relief (time for return to baseline value ± SEM compared with placebo, 8.3 ± 2.4 hours; P = .027) and desloratadine (4.5 ± 1.2 hours, P = .030). One interesting finding was that Ze 339 significantly reduced IL-8 and leukotriene B4 levels in nasal secretions before challenge. Conclusion: When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis.
KW - IL-8
KW - Petasites hybridus
KW - Randomized controlled trial
KW - Ze 339
KW - allergic rhinitis
KW - desloratadine
KW - histamine
KW - nasal allergen challenge
KW - nasal obstruction
KW - petasol butenoate complex
KW - rhinomanometry
UR - http://www.scopus.com/inward/record.url?scp=79957806285&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2011.02.045
DO - 10.1016/j.jaci.2011.02.045
M3 - Article
AN - SCOPUS:79957806285
SN - 0091-6749
VL - 127
SP - 1515-1521.e6
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -